1. Home
  2. BTCT vs BYSI Comparison

BTCT vs BYSI Comparison

Compare BTCT & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTCT

BTC Digital Ltd.

N/A

Current Price

$1.28

Market Cap

29.9M

Sector

Real Estate

ML Signal

N/A

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

N/A

Current Price

$0.76

Market Cap

31.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTCT
BYSI
Founded
2006
2010
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.9M
31.4M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
BTCT
BYSI
Price
$1.28
$0.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.4M
112.1K
Earning Date
05-29-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$283.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.57
52 Week High
$3.12
$2.44

Technical Indicators

Market Signals
Indicator
BTCT
BYSI
Relative Strength Index (RSI) 50.43 48.62
Support Level $1.13 $0.58
Resistance Level $1.89 $1.25
Average True Range (ATR) 0.23 0.06
MACD -0.07 0.04
Stochastic Oscillator 8.75 84.84

Price Performance

Historical Comparison
BTCT
BYSI

About BTCT BTC Digital Ltd.

BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: